We have previously shown that Epstein-Barr virus (EBV)-encoded EBNA-5 is localized to PML bodies (PODs) in EBV-immortalized lymphoblastoid cell lines (LCLs
Introduction
Epstein-Barr virus (EBV) is the most potent transforming virus known. EBV infection of resting B cells in vitro induces blast transformation and leads to the establishment of immortal lymphoblastoid cell lines (LCLs). This process is associated with the expression of nine latent viral proteins : the nuclear antigens, EBNA1-6, and three membrane proteins, LMP-1, -2a and -2b. Six of these proteins are required for immortalization : EBNA-1, -2, -3 (3A), -5 (LP), -6 (3C) and LMP-1 (Rickinson & Kieff, 1996) .
EBNA-5 and EBNA-2 are the first virally encoded proteins expressed after B cell infection (Alfiery et al., 1991) . They can drive gp340-activated primary B cells into the G " phase of the cell cycle (Sinclair et al., 1994) . This suggests that EBNA-5 may play a role at the first steps of EBV transformation. EBNA-5 can co-operate with EBNA-2 in the activation of LMP-1 and Cp Author for correspondence : Katja Pokrovskaja.
Fax j46 8 33 04 98. e-mail katpok!ki.se viral promoters (Harada & Kieff, 1997) . The co-transfection of EBNA-3 and EBNA-5 into the DG75 line showed that EBNA-3 is tethered to the nuclear matrix fraction in the presence of EBNA-5 (Cludts & Farrell, 1998) . This suggested that EBNA-5 may modify the intranuclear sorting of proteins.
After EBV infection of B cells, EBNA-5 is homogeneously distributed in the nucleus during the first 2 days. Later it accumulates in PML bodies or PODs (PML oncogenic domains ; Szekely et al., 1995 Szekely et al., b, 1996 . These are distinct nuclear domains associated with the nuclear matrix. PML, in complex with SUMO-1, is required to form the POD structure (Ishov et al., 1999 ; . PODs are specifically disrupted in human acute promyelocytic leukaemia cells where PML is fused to a retinoic acid receptor alpha gene. A number of cellular proteins are localized to the PODs : SP100, INT6, CBP\p300, Hsp70, a fraction of Rb, Daxx and SUMO-1 (for review see Zhong et al., 2000 b) . Herpes simplex virus type 1 infection abrogates the modification of PML by SUMO-1 (Muller & Dejean, 1999) , leading to rapid PML protein degradation (Chelbi-Alix & de The, 1999 ) and disruption of the (A) Double-staining of endogenously and exogenously expressed EBNA-5 and PML. LCL IARC171 expresses endogenous EBNA-5 that localized to both PML bodies and the nucleoplasm (upper row). BL line, DG75, and breast cancer line, MCF-7, were stably transfected with pBabe-EBNA-5. EBNA-5 was homogeneously distributed in the nucleoplasm and did not co-localize with PML (middle and lower row, respectively). (B) IARC171 (upper row), DG75 (middle row) and MCF-7 (lower row) were transfected with GFP-EBNA-5 and stained for PML 2 days later. GFP-EBNA-5 targeted PML bodies in IARC171, but not in DG75 or MCF-7. Red, PML ; green, EBNA-5 ; blue, nuclei. PODs. The EBV growth and transformation-associated EBNA-5 localizes to the PODs without disrupting them (Szekely et al., 1996) . PML expression is induced by interferons. Cellular response to interferon requires normal PML function (Quignon et al., 1998 ; Wang et al., 1998) . PML was recently shown to regulate MHC expression in untransformed fibroblasts and to induce the expression of the proteins involved in antigen processing and presentation (Zheng et al., 1998) . The ubiquitinproteasome system is involved in the processing of MHC class I antigens, providing a link between the cellular degradation machinery and PML. The ubiquitin-proteasome system is the major pathway of selective protein degradation in eukaryotic cells. Initially, the target proteins are conjugated to the polypeptide ubiquitin through a lysine residue on the proteins. In the second step, the ubiquitin-conjugated proteins are recognized by the 26S proteasome and degraded (for review see Ciechanover, 1998) . It is likely that nuclear POD structures are involved in this process. A protein genetically modified for rapid degradation can accumulate in the ubiquitinated form in the PODs upon proteasome inhibitor treatment. This was accompanied by the attraction of the proteasomes to the PODs, suggesting that the PODs may represent an intermediate reservoir for the ubiquitinated proteins targeted for degradation (Anton et al., 1999) .
In an attempt to understand the role of EBNA-5 targeting to the PML bodies and in proteasome-mediated protein degradation, we monitored the changes in subcellular localization and in the total EBNA-5 levels upon proteasome inhibitor treatment. We have also continued to analyse the subnuclear localization of EBNA-5 in different cell types and found that EBNA-5 targets preferentially the PODs in the LCLs and in the BLs with an LCL-like phenotype. Nucleoplasmic localization was found in other cell types. Independently of EBNA-5 localization to the PODs or to the nucleoplasm, EBNA-5 translocated to the nucleoli when the cells were treated with proteasome inhibitor MG132.
Methods
Cell lines, culture conditions and transfections. All cell lines were grown in Iscove's cell culture medium supplemented with 10 % heat-inactivated FBS, 2 mM -glutamine, 100 U\ml penicillin and 100 U\ml streptomycin. The cells were passaged every fourth day 1 : 5. Cultures were regularly tested for the absence of mycoplasma. Transfections were done using Lipofectamine Plus reagent (GibcoBRL) according to the manufacturer's instructions. MCF-7, a breast carcinoma line bearing wild-type p53, was obtained from M. Oren, The Weizmann Institute of Science, Israel. SW480 is a colorectal cancer line bearing mutant p53 (Arg to His 273 and Pro to Ser 309 ; Abarzua et al., 1995 and references therein) . DG75 is an EBV-negative BL line (Ben-Bassat et al., 1977) . IB-4 is an EBV-transformed LCL (King et al., 1980) . Clones of HeLa, MCF-7 and SW480 lines stably expressing EBNA-5 from a pBabe-EBNA-5 construct were generated using selection with 1 µg\ml puromycin (Sigma). Proteasome inhibitor MG132 was purchased from Calbiochem, diluted in DMSO and used at concentrations of 5-20 µM for the 6-16 h treatment of cells. The control cells were incubated with the same amounts of DMSO. GFP-EBNA-5 was made by cloning an EBNA-5-encoding BamHI-EcoRI fragment from pBabe-EBNA-5, containing four W repeats and the unique C-terminal region, into BglII-EcoRI-cleaved pEGFP-C1 (Clontech).
Antibodies, immunostainings and Western blotting.
The following antibodies were used in this study for immunofluorescence and Western blotting : MAb D07 against p53 (DACO) ; MAb JF186 against EBNA-5 ( Finke et al., 1987) and biotinylated JF186 (GibcoBRL biotinylation kit was used) ; MAb Ab-1 against Hsp72\73 (Oncogene Science) ; MAb pe2 against EBNA-2 (a gift from M. Rowe, University of Wales College of Medicine, UK) ; and MAb CS1-4 against LMP-1 (DACO). MAb against B23\nucleophosmin was a gift from P. K. Chan, Baylor College of Medicine, Houston, USA ; rabbit serum against PML was a gift from H. de The, Institut d'Hematologie de l'Universite Paris VII, Paris, France. Cells were fixed in cold methanol-acetone, rehydrated for 30 min, stained with primary MAb for 1 h followed by three washes in PBS, incubated with secondary FITC or Texas red-conjugated antibodies, washed three times and mounted with 80 % glycerol solution in PBS containing 2n5 % 1,4-diazabicyclo-(2.2.2)octane (Sigma). Bisbenzimide (Hoechst 33258) was added at a concentration of 0n4 µg\ml to the secondary antibody for DNA staining. The double stainings for Hsp70 and EBNA-5 were done as follows : Ab-1 against Hsp70\rabbit-anti-mouse FITC-conjugated (DACO)\normal mouse serum\biotiny-lated JF186\Texas red-conjugated streptavidin (Vector). FITCconjugated goat-anti-mouse and Texas red-conjugated goat-anti-rabbit (Vector) secondary antibodies were used for double EBNA-5\PML stainings.
The images were recorded on a DAS microscope Leitz DM RB with a Hamamatsu dual mode cooled CCD camera C4880. Alternatively, a fluorescence 3D microscope was used to reconstitute the image from a series of optical sections that were deblurred using the nearest neighbour algorithm with the help of the computer program TROOPER3, developed by us (Holmvall & Szekely, 1999) . The original graphics files are available as 8 and 24 bit uncompressed TIFF images at our anonymous FTP site at ftp :\\130.237.124.100\E5LLL.
Total cell extracts were prepared by direct lysis in a hot Laemmli buffer. Proteins were separated on 10 % SDS-PAGE followed by transfer to nitrocellulose membrane (Schleicher & Schuell). Blocking and incubation with antibodies were performed in 5 % milk in PBS and 0n2% Tween 20. Immunodetection using the ECL system (Amersham) was performed according to the manufacturer's instructions.
Results

Both endogenously and exogenously expressed EBNA-5 co-localize with PML in the LCLs
We have previously shown that EBNA-5 co-localized with PML in LCL IB-4 and after EBV infection of peripheral B cells (Szekely et al., 1996) . In order to see whether ectopically expressed EBNA-5 targets the same nuclear compartment, we have created a construct expressing a GFP-EBNA-5 fusion protein that can be directly detected in cells. LCL IARC171 was transfected with this construct by electroporation. IARC171 expressed low amounts of endogenous EBNA-5, detectable in 1-3 % of cells by immunostaining, localized to both nucleoplasm and the PODs (Fig. 1 A, upper row) . Staining DFA of the cells 2 days after GFP-EBNA-5 transfection with anti-PML MAb showed that GFP-EBNA-5 co-localized with PML in IARC171 (Fig. 1 B, upper row) .
Partial co-localization of EBNA-5 and PML in B and non-B cells BL DG75 was transfected with the pBabe-EBNA-5 construct and a puromycin-resistant pool was tested for the pattern of EBNA-5 expression. The protein localized to the nucleoplasm (Fig. 1 A, middle row) . Transient transfection of BL lines DG75 and BL 28 with GFP-EBNA-5 showed nuclear localization and only seldom targeting of the PML bodies ( Fig.  1 B, middle row and not shown). The EBV-positive BL lines cultured in vitro change their original, BL tumour phenotype to an immunoblastic, LCL-like phenotype, and activate the expression of EBNAs and LMPs . In one such line, Namalwa, EBNA-5 was localized to both nucleoplasm and PODs (not shown).
We have established clones of SW480 (clones S2, S8, S9) and MCF-7 (clones M1, M2, M3 and M5) that ectopically express EBNA-5. The clones were double-stained for PML and EBNA-5. EBNA-5 was homogeneously distributed in the nucleoplasm, avoiding the nucleoli in all lines mentioned, and did not co-localize with PML. This is shown for MCF-7 clone M5 ( Fig. 1 A, lower row) and MCF-7 transiently transfected with GFP-EBNA-5 (Fig. 1 B, lower row) . Transiently transfected GFP-EBNA-5 often accumulates in conglomerates of irregular shape, seen in one of the cells in Fig. 1 (B) , which do not co-localize with PML.
EBNA-5 translocates to the nucleoli after treatment with proteasome inhibitor MG132
Clones M1, M2 and M3 of MCF-7 expressed EBNA-5 at moderate levels and showed primarily homogeneous nuclear staining as shown in Fig. 2 (A, panel a) for M1. Treatment with 20 µM of MG132 for 6 h led to a nearly complete translocation of EBNA-5 to the nucleoli (Fig. 2 A, panel c) . The phase contrast fields are shown in Fig. 2 (A, panels b and d) to visualize the cells and the nucleoli. In order to prove the localization of EBNA-5 to the nucleolus, we double-stained M1 cells for EBNA-5 and nucleophosmin\B23 after MG132 treatment. Fig. 2 (B) shows that EBNA-5 is localized deep inside the nucleoli and is surrounded by the B23 protein. The pattern of B23 staining was not changed by MG132 treatment (not shown).
LCL IB-4 expressed endogenous EBNA-5 that was colocalized with PML (Szekely et al., 1996) and Fig. 3 (A, left  panels) . EBNA-5 and PML partially dissociated and the former accumulated in the nucleoli after treatment of IB-4 with 5 µM of MG132 for 6 h (Fig. 3 A, right panels and C for EBNA-5 and phase contrast). We have also tested the localization of other EBV-encoded proteins and found that neither EBNA-2 (Fig. 3 B) nor EBNA-6 (not shown) nor LMP-1 (Fig. 3 B) changed their localization after MG132 treatment.
Hsp70 co-localizes with EBNA-5 and accumulates in the nucleoli of MG132-treated cells
We have shown previously that EBNA-5 co-localized with constitutively expressed Hsp70 in IB-4 cells under normal conditions and upon heat shock (Szekely et al., 1995 a) . EBNA-5 and Hsp70 co-localized in the nucleoli of IB-4 cells treated with MG132 for 6 h (Fig. 3 C) .
Exogenously expressed EBNA-5 co-localized with Hsp70 in clone M5 in the nucleoplasm (MCF-7 transfected with EBNA-5, Fig. 4 A) . This shows that localization to PML bodies is not a prerequisite for EBNA-5\Hsp70 co-localization. We noticed an increase in nuclear staining of Hsp70 in the clones of MCF-7 and SW480 expressing EBNA-5, as compared to the vector-transfected cells (Fig. 4 B, panel b and not shown). This suggests that EBNA-5 tethers Hsp70 to the nucleus.
The antibody against Hsp70 recognizes both the inducible Hsp72 and the constitutive Hsc73 proteins. In untreated cells, Hsp70 showed homogeneous nuclear and cytoplasmic distribution (Fig. 4 B, panel b) . Upon MG132 treatment, Hsp70 completely changed its localization : it accumulated in the cytoplasm and nucleoli (Fig. 4 B, panel f) . EBNA-5 translocated to the nucleoli (Fig. 4 B, compare panels a and e). Clone M5, in which only 10 % of cells express high EBNA-5 levels, was chosen to demonstrate that the changes in the Hsp70 localization were independent of EBNA-5. We noticed, however, that cells expressing higher levels of EBNA-5 showed a stronger Hsp70 staining in the nucleoli (Fig. 4 A, panels e, f,  g ). The same phenomenon was observed in the MG132-treated S2 clone of SW480 that expressed EBNA-5.
Total protein levels were monitored by Western blotting (Fig. 4 C) . EBNA-5 levels did not change after MG132 treatment in IB-4, the H6 clone of HeLa expressing EBNA-5 or clone M5 of MCF-7. Even 16 h treatment did not change the EBNA-5 levels in clone M1 (Fig. 4 C, lower panel) . Hsp70 levels were increased and a faster migrating band, representing the inducible Hsp72 protein, appeared in all MG132-treated cells including the EBNA-5-negative HeLa clone H4. This again demonstrates that Hsp70 is induced in response to MG132 and that this induction is independent of EBNA-5.
In order to test the effect of proteasome inhibition, we probed the same membrane with antibodies against p53, a short-lived protein degraded through the proteasome pathway. The presence of EBNA-5 did not change the levels of wild-type p53 in MCF-7 or in HeLa cells. MG132 treatment led to the accumulation of wild-type p53 in IB-4 and MCF-7 cells with the appearance of ubiquitinated forms of the protein in accordance with previously published data (Kubbutat et al., 1997) . In HeLa cells, p53 is complexed with human papillomavirus-encoded E6 protein, which targets p53 for degradation. The inhibition of proteasome activity has led to the DFB K. Pokrovskaja and others K. Pokrovskaja and others 
Presence of EBNA-5 enhances translocation of mutant p53 to the nucleoli of SW480 cells upon treatment with proteasome inhibitor
The colorectal cancer line SW480 expresses endogenous mutant p53 at high levels. p53 is localized to the nuclei, mainly avoiding the nucleoli (Fig. 5 A, panels c and e) . P2 and S2 are pBabe vector-and pBabe-EBNA-5-transfected derivatives of SW480. The presence of EBNA-5 did not change the levels of mutant p53 (compare Fig. 5 A, panels c and e) . Treatment with 20 µM of MG132 for 6 h led to a nearly complete translocation of EBNA-5 to the nucleoli of S2 (Fig. 5 A, panels a and b) , to a partial accumulation of mutant p53 in the nucleoli in 10 % of the P2 cells (Fig. 5 A, panel f) and to a significant p53 accumulation in the nucleoli in 90 % of S2 cells (Fig. 5 A, panel  d) . Fig. 5 (B) shows p53 inside the nucleoli in the MG132-treated S2 cells at high magnification. In order to substantiate this finding, we double-stained MG132-treated S2 cells for EBNA-5 and p53. Fig. 5 (C) shows that p53 is preferentially accumulated in the nucleoli of cells when EBNA-5 is also in the nucleoli (arrows). In contrast, cells without EBNA-5 (square sign) or those where EBNA-5 has not changed its localization (asterisks) showed homogeneous p53 staining. These results show that EBNA-5 greatly enhances accumulation of mutant p53 in the nucleoli upon inhibition of proteasome activity.
The inhibition of wild-type p53 degradation by MG132 in MCF-7 cells led to the accumulation of the protein and its ubiquitinated forms (Fig. 4 C) in both nucleus and nucleolus (Fig. 6, panel d and phase contrast in panel f) . Transient expression of GFP-EBNA-5 (Fig. 6 , panels a and b) had no effect on the intranuclear distribution of wild-type p53 upon MG132 treatment (Fig. 6, panel d) . Arrows point to the MG132-treated cell expressing GFP-EBNA-5 that has translocated to the nucleoli.
Discussion
We have found that the treatment of different EBNA-5-expressing cell lines with a proteasome inhibitor, MG132, led to a dramatic change in the distribution of EBNA-5, namely its almost complete translocation to the nucleoli. MG132 increased the levels of the cellular chaperon Hsp70 in agreement with previously published data (Bush et al., 1997 ; Kim et al., 1999) . We have found in addition that MG132 induced a nucleolar accumulation of Hsp70. The Hsp70 proteins are involved in protein folding, protein translocation across membranes and thermal tolerance. In nonstressed cells, Hsp70 associates transiently with nascent polypeptide chains, polypeptides unfolded for translocation or other aberrantly folded proteins (for review see Hightower, 1991) . Both major members of the Hsp70 family, the stressinducible Hsp72 and the constitutive cognate Hsc73, were found to associate with the soluble form of EBNA-5 in coimmunoprecipitation experiments. The W " W # -repeats in the EBNA-5 protein were required for binding (Mannick et al., 1995) . Another study showed that the Y # C-terminal exon region of EBNA-5 formed complexes with Hsp70 (Kitay & Rowe, 1996) . We have found previously that EBNA-5 is colocalized with Hsp70 in PODs in the LCL IB-4 under normal conditions and in the nucleoli upon heat shock (Szekely et al., 1995 a) . Both Hsp72 and Hsc73 accumulate in the nucleoli in heat-shocked mammalian cells (for review see Hightower, 1991) . We found that Hsp70 localized to the nucleoli upon MG132 treatment, independently of the presence or absence of EBNA-5. Considering the direct binding of EBNA-5 to Hsp70, it is possible that the latter transports EBNA-5 into the nucleoli. On the other hand, Hsp70 accumulated in the nucleoplasm of the EBNA-5-, but not the vector controltransfected clones of MCF-7 and SW480 (Fig. 4 A and not  shown) . It also showed a high degree of co-localization with EBNA-5 in the nucleoplasm, suggesting that EBNA-5 expression recruits Hsp70 into complex formation. The nucleolar localization of Hsp70 in proteasome inhibitor-treated cells was enhanced by the presence of EBNA-5 (Fig. 4 B) , suggesting that there is an active component in the translocation of EBNA-5 to the nucleoli rather than passive transport by Hsp70.
EBNA-5 is strongly associated with the nuclear matrix (Szekely et al., 1995 a) . It can also tether another EBV-encoded nuclear protein, EBNA-3, to the nuclear matrix upon cotransfection (Cludts & Farrell, 1998) . This suggests that EBNA-5 can influence the subnuclear localization of other proteins and therefore it may play a scaffolding role by forming bridges between the nuclear matrix and nucleoplasmic proteins.
We found in this study that EBNA-5 greatly enhanced the accumulation of a mutant, but not wild-type, p53 in the nucleoli upon MG132 treatment. Mutations in p53 lead to misfolding of the protein. Mutant p53 forms complexes with Hsp70 (Pinhasi-Kimhi et al., 1986) . The high affinity binding sites for these proteins were mapped to the hydrophobic core of the central DNA binding domain, not accessible in a wildtype conformation (Fourie et al., 1997) . In the absence of EBNA-5, mutant p53 was only rarely found in the nucleoli of MG132-treated cells. Our study suggests that EBNA-5 targets mutant p53 to the nucleoli upon proteasome inhibitor DFD K. Pokrovskaja and others K. Pokrovskaja and others treatment. GST-EBNA-5 could precipitate mutant p53 from SW480 and Namalwa cell lysates (Szekely et al., 1993) . It is possible that EBNA-5 and Hsp70 form tri-component complexes with the misfolded mutant p53 that translocate to the nucleolus much more efficiently than the Hsp70-mutant p53 complex. The absence of the EBNA-5 effect on wild-type p53 distribution upon MG132 treatment supports this notion.
Alternatively, EBNA-5 binds and translocates mutant p53 independently of Hsp70.
The nucleoli are special nuclear domains involved in rRNA synthesis (fibrillar compartment) and ribosome formation (granular compartment). Nucleolar proteins are involved either in rRNA synthesis and processing or in ribosome assembly (for review see Scheer & Hock, 1999) . The involvement of the DFF K. Pokrovskaja and others K. Pokrovskaja and others nucleoli in proteasome-mediated protein degradation has not been documented. Our data on proteasome inhibitor-induced nucleolar accumulation of Hsp70, EBNA-5 and p53 may suggest that nucleoli can be involved in proteasome-dependent protein degradation.
EBNA-5 accumulates in the PML bodies in cells with an immunoblastic phenotype but not in type I BLs or in non-B cells, suggesting the presence of EBNA-5-associated, B-blastspecific nuclear factors that target EBNA-5 into the PODs. Alternatively, it may require an additional EBV-encoded protein(s) or EBV genome in order to localize to the PODs.
It has been suggested that PML bodies are the nuclear analogues of the aggrosomes that feed proteasomes with ubiquitinated substrates (Anton et al., 1999) . PML bodies also contain Hsp70 even in unstressed cells (Szekely et al., 1995 a) , suggesting that misfolded nuclear proteins might accumulate in the PODs. It seems unlikely that EBNA-5 itself is degraded through the proteasome pathway since it does not contain lysines, which are the targets for ubiquitination. Also, our Western blot data showed no increase in EBNA-5 protein levels upon MG132 treatment in different cell lines even after 16 h of proteasomal block. It seems therefore unlikely that the PML bodies provide an intermediate reservoir for EBNA-5 on its way for degradation. On the other hand, our data suggest that POD-associated EBNA-5 might regulate the proteasomemediated degradation of other proteins.
The PML bodies might be indirectly involved in transcription regulation by coordinating the degradation of transcription factors. Transcription co-activators such as CBP\ p300, transcriptional repressors, such as Daxx and Tax, and the tumour suppressor protein Rb were detected in the PODs (for review see Zhong et al., 2000 b) . EBNA-5 was found to enhance EBNA-2-mediated transactivation of EBV promoters (Harada & Kieff, 1997) . The mechanism of this co-operation is not known. Our data raise the possibility that EBNA-5 might cooperate with EBNA-2 through modifying the degradation rate of transcription regulators.
